Prostate Cancer Clinical Trial
— PeP-RALPOfficial title:
Perioperative Propranolol in Robotic Assisted Laparoscopic Prostatectomy- A Feasibility Study of Propranolol to Target Perioperative Stress Induced Cancer Progression
The purpose of this study is to assess the feasibility of conducting a larger randomized controlled trial to assess the efficacy of perioperative propranolol capsules compared with placebo capsules in decreasing recurrence of prostate cancer after robotic assisted laparoscopic prostatectomy (RALP) in participants with intermediate to high-risk for prostate cancer recurrence.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | October 1, 2023 |
Est. primary completion date | October 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 40 Years to 80 Years |
Eligibility | Inclusion Criteria: - European Association of Urology Intermediate- and High Risk for Biochemical recurrence and planned for curative RALP - ECOG Performance Status 0-1 Exclusion Criteria: Medical Conditions 1. Sick sinus syndrome 2. Atrioventricular (AV) block grade 2 and 3 3. Recent (3 months) myocardial infarction 4. Known unstable- or vasospastic- angina 5. Heart failure (New York Heart Association [NYHA] > 2) 6. Symptomatic peripheral vascular disease (e.g. intermittent claudication) 7. Known pulmonary hypertension 8. Known carotid artery stenosis or recent (3 months) stroke 9. Bronchial asthma or other chronic obstructive pulmonary disease (COPD) 10. Kidney failure (estimated Glomerular filtration rate [eGFR]<50) 11. Liver failure (cirrhosis, jaundice, signs of hepatic decompression) 12. Unregulated diabetes mellitus 13. Untreated thyroid disorder 14. Depressive episode within last 6 months (within last 12 months if major depressive episode) 15. Known drug allergy against propranolol or excipients 16. Any medical conditions considered to prohibit Propranolol use as judged by the treating physician (including frailty). 17. Participants with known substance- or alcohol-abuse Prior/Concomitant Therapy 18. Recent (<3 month) use of systemic beta-blockers prior to screening. 19. Patients receiving non-dihydropyridine calcium channel blocking agents (eg diltiazem, verapamil) 20. Patients receiving anti-arrhythmic agents (e.g. amiodarone, sotalol, digoxin, verapamil, flecainide) 21. Patients receiving digoxin, rizatriptan, hydralazine, fluvoksamin, or fluoksetin 22. Patients using daily anxiolytics (e.g. benzodiazepines), alpha-receptor adrenergic agonists (e.g. clonidine) 23. Recommendations in the Summary of Product Characteristics for propranolol regarding concomitant use of other medications will be adhered to. Diagnostic assessments 24. Sinus bradycardia (<60 beats/minute) 25. Resting blood pressure <110/60mmHg OR hypertension BP >160/100 26. AV-block on ECG |
Country | Name | City | State |
---|---|---|---|
Norway | Oslo University Hospital The Norwegian Radium Hospital | Oslo |
Lead Sponsor | Collaborator |
---|---|
Oslo University Hospital |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in perceived distress during the study. | Investigate alterations in perioperative perceived distress, assessed by Hospital Anxiety and Depression Scale (HADS) | Up to 9 weeks | |
Other | Immunohistochemistry and Image mass cytometry of tumor to assess for differences between treatment arms. Flow cytometry to assess of periferal blood to assess for differences between treatment arms. | Immunohistochemistry and image mass cytometry to assess for differences between treatment arms in intra-tumor immune cell infiltration. Flow cytometry to assess differences between treament arms in systemic immune cell acitivity. |
Up to 9 weeks | |
Other | Difference in prognostic markers (e.g. Decipher GRID transcriptome analysis) between treatment arms. Identify predictive biomarkers for propranolol responsiveness (e.g. Decipher GRID transcriptome analysis) | Determine the effect of pre-operative propranolol treatment on prognostic markers and assess for predictive biomarkers. Identify predictive biomarkers for propranolol responsiveness. | up to 1 year | |
Other | Differences between intervention arms with regard to intraoperative alterations in cerebral autoregulation and intracranial pressure, measured by transcranial doppler (TCD) floe velocity. | Intraoperative alterations in cerebral autoregulation and intracranial pressure by Transcranial Doppler flow velocity measurement of the middle cerebral artery. | up to 1 year | |
Primary | The feasibility of conducting a formal larger RCT to compare the efficacy of propranolol vs placebo to decrease PCa recurrence following RALP. | Numbers of eligible participants needed to screen to include 40 patients in the study, reported as % of eligible participants that subsequently were included in the study. Compliance of study intervention (defined as >80% of doses taken). Reported as % of participants compliant to the study intervention before RALP and % of participants compliant to the study intervention after RALP. |
The feasability will be assessed after the 6-9 months. The total duration of study participation from screening to end of follow-up is 50-102 days per participant. | |
Secondary | Safety and tolerability of PeP-RALP intervention | Safety: Proportion (%) of patients experiencing treatment related clinical significant hypotension and/or bradycardia. Adverse events of PeP-RALP medication as assessed by CTCAE v5.0. Tolerability: Proportion (%) of patients tolerating daily dose of 80mg propranolol. |
9 weeks | |
Secondary | Determine the effect of RALP on catecholamine levels | Changes in catecholamine levels in the perioperative period. | Up to 5 weeks | |
Secondary | Determine the bioavailability of propranolol | Serum levels of propranolol pre-operatively and at end of PeP-RALP medication. | Up to 5 weeks | |
Secondary | Determine the effect of preoperative propranolol treatment on the serum level of PSA | Changes in PSA levels after 7-14 days of PeP-RALP medication. | 7-14 days | |
Secondary | To determine the effect of propranolol on post-operative biochemical failure | Proportion of patients with serum PSA levels above 0.1 ng/ml at 6 weeks post-RALP. | Up to 9 weeks | |
Secondary | Intraoperative anesthesiological and surgical challenges Surgical complications in PeP RALP patients | Anesthesiological challenges are assed by: Proportion of patients (%) in each intervention group requiring vasopressors to maintain an acceptable mean arterial pressure (MAP >60mmhg). Amount of vasopressor needed. Surgical challenges are assed by: The surgical procedure time (minutes) and estimated intraoperative blood loss (milliliters). |
1 day | |
Secondary | Surgical complications | Frequence (n=) and severity of surgical complications as classified by the Clavian-Dindo classification. | Up to 9 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |